Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Trade Show, Webcast

PhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference


PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, at 12:00 p.m. EDT.

The event will be available via live webcast from the "Events and Presentations" page of the "Investors" section of the company's website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company's pipeline includes: PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor; PB1046, a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension and hospitalized COVID-19 patients at high risk for rapid clinical deterioration and ARDS; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio's proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including PB1046, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com.


These press releases may also interest you

at 21:00
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

at 19:30
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

at 19:05
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:51
Banco Latinoamericano de Comercio Exterior, S.A. , a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced...

at 17:20
Providing a comprehensive overview of NOVAGOLD's Environmental, Social and Governance (ESG) performance, emphasizing remarkable health and safety records, steadfast dedication to environmental protection, continuous community investment, extensive...

at 16:45
Dogness (International) Corporation ("Dogness" or the "Company") , a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced its financial results for the six months ended December...



News published on and distributed by: